Genmab reported DKK584M in Net Income for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Agios Pharmaceuticals AGIO:US USD 36.53M 118.27M
Amarin AMRN:US USD -5140000 64.82M
Amgen AMGN:US USD 1.62B 527M
Artemis Alpha ATS:LN GBP -26769000 16.52M
AstraZeneca AZN:LN USD 901M 739M
Bayer BAYN:GR EUR 611M 65M
Biomarin Pharmaceutical BMRN:US USD -249000 6.4M
Bluebird Bio BLUE:US USD -76520000 23.62M
Exelixis EXEL:US USD -30173000 103.38M
Fresenius Medical Care FME:GR EUR 138.8M 91.3M
Galapagos GLPG:NA EUR -207207000 228.76M
Genmab GEN:DC DKK 584M 2B
GlaxoSmithKline GSK:LN GBP 1.5B 8.82B
GN Store Nord GN:DC DKK 263M 66M
Hikma Pharmaceutical HIK:LN USD 15M 158M
Immunogen IMGN:US USD -59008000 18.75M
Insmed INSM:US USD -160123000 28.98M
Lonza Group LONN:SW CHF 723M 231M
Merck MRK:GR EUR 654M 269M
Novartis NOVN:VX USD 1.47B 107M
Regeneron Pharmaceuticals REGN:US USD 1.2B 118.6M
Roche Holding ROG:VX 3.89B 4.64B
Seattle Genetics SGEN:US USD -148171000 42.64M
William Demant Holding WDH:DC DKK 1.03B 16M